Evelo Biosciences, Inc.
Evelo Biosciences, Inc. (EVLO) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · EVLO · as of Jun 9, 2026
Activity summary
Buy transactions
3
P-Purchase only
Sell transactions
18
12 Months
Buy/Sell ratio
0.17
Buy/Sell (by trades)
Overall sentiment
Evelo Biosciences, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
EVLO insider buying and selling by quarter
EVLO insider selling · EVLO insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
EVLO executive sell shares · EVLO board member insider trading · EVLO insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Nov 7, 2023 | Bodmer Mark CSO, President of R&D | Option | 6,625 | — | Form 4 |
| Nov 8, 2023 | Bodmer Mark CSO, President of R&D | Sale | 3,163 | $1K | Form 4 |
| Nov 7, 2023 | McHale Duncan Chief Medical Officer | Option | 6,500 | — | Form 4 |
| Nov 8, 2023 | McHale Duncan Chief Medical Officer | Sale | 3,103 | $1K | Form 4 |
| Nov 7, 2023 | GILL SIMBA President & CEO · Director | Option | 1,172 | — | Form 4 |
| Nov 8, 2023 | GILL SIMBA President & CEO · Director | Sale | 172 | $57 | Form 4 |
| Nov 7, 2023 | Thorell Marella CFO | Option | 6,500 | — | Form 4 |
| Nov 8, 2023 | Thorell Marella CFO | Sale | 1,811 | $598 | Form 4 |
| Nov 1, 2023 | Bodmer Mark CSO, President of R&D | Option | 12,500 | — | Form 4 |
| Nov 2, 2023 | Bodmer Mark CSO, President of R&D | Sale | 6,854 | $2K | Form 4 |
| Nov 1, 2023 | McHale Duncan Chief Medical Officer | Option | 12,500 | — | Form 4 |
| Nov 2, 2023 | McHale Duncan Chief Medical Officer | Sale | 6,854 | $2K | Form 4 |
| Nov 1, 2023 | Thorell Marella CFO | Option | 12,500 | — | Form 4 |
| Nov 2, 2023 | Thorell Marella CFO | Sale | 3,999 | $1K | Form 4 |
| Sep 27, 2023 | GILL SIMBA President & CEO · Director | Option | 15,000 | — | Form 4 |
| Sep 28, 2023 | GILL SIMBA President & CEO · Director | Sale | 1,996 | $8K | Form 4 |
| Aug 7, 2023 | Bodmer Mark CSO, President of R&D | Option | 6,625 | — | Form 4 |
| Aug 8, 2023 | Bodmer Mark CSO, President of R&D | Sale | 3,128 | $30K | Form 4 |
| Aug 7, 2023 | GILL SIMBA President & CEO · Director | Option | 1,171 | — | Form 4 |
| Aug 8, 2023 | GILL SIMBA President & CEO · Director | Sale | 342 | $3K | Form 4 |
| Aug 7, 2023 | McHale Duncan Chief Medical Officer | Option | 6,500 | — | Form 4 |
| Aug 8, 2023 | McHale Duncan Chief Medical Officer | Sale | 3,434 | $33K | Form 4 |
| Aug 7, 2023 | Thorell Marella CFO | Option | 6,500 | — | Form 4 |
| Aug 8, 2023 | Thorell Marella CFO | Sale | 2,004 | $19K | Form 4 |
| Jul 11, 2023 | Flagship Ventures Fund IV General Partner LLC 10 percent owner | Purchase | 3,246,753 | $7.50M⚡ | Form 4 |
GILL SIMBA
President & CEO · Director
Date
Sep 28
Shares
1,996
Price
$3.94
Value
$8K
Flagship Ventures Fund IV General Partner LLC
10 percent owner
Date
Jul 11
Shares
3,246,753
Price
$2.31
Value
$7.50M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About EVLO insider trading
EVLO insider trades
Evelo Biosciences, Inc. (EVLO) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including EVLO. Over the past 12 months, 0 insiders have filed transactions with the SEC. EVLO insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Evelo Biosciences, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
EVLO insider trading · 5 questionsThe insiders of Evelo Biosciences, Inc. (EVLO) include executives and directors such as EVLO, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026